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Objective: The primary aim of this study was to longitudinally compare the behavioral
and self-reported outcomes of simultaneous bilateral cochlear implantation (simBiCI)
and sequential BiCI (seqBiCI) in adults with severe-to-profound postlingual sensorineural
hearing loss.
Design: This study is a multicenter randomized controlled trial with a 4-year follow-
up period after the first moment of implantation. Participants were allocated by
randomization to receive bilateral cochlear implants (CIs) either, simultaneously (simBiCI
group) or sequentially with an inter-implant interval of 2 years (UCI/seqBiCI group). All
sequential patients where encouraged to use their hearing aid on the non-implanted
ear over of the first 2 years. Patients were followed-up on an annual basis. The
primary outcome was speech perception in noise coming from a source directly in
front of the patient. Other behavioral outcome measures were speech intelligibility-in-
noise from spatially separated sources, localization and speech perception in quiet.
Self-reported outcome measures encompassed questionnaires on quality of life, quality
of hearing and tinnitus. All outcome measures were analyzed longitudinally using a
linear or logistic regression analysis with an autoregressive residual covariance matrix
(generalized estimating equations type).
Results: Nineteen participants were randomly allocated to the simBiCI group and 19
participants to the UCI/seqBiCI group. Three participants in the UCI/seqBiCI group did
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not proceed with their second implantation and were therefore unavailable for follow-
up. Both study groups performed equally well on speech perception in noise from a
source directly in front of the patient longitudinally. During all 4 years of follow-up the
UCI/seqBiCI group performed significantly worse compared to the simBiCI group on
spatial speech perception in noise in the best performance situation (8.70 dB [3.96 –
13.44], p < 0.001) and localization abilities (largest difference 60 degrees configuration:
−44.45% [−52.15 – −36.74], p < 0.0001). Furthermore, during all years of follow-up,
the UCI/seqBiCI group performed significantly worse on quality of hearing and quality
of life questionnaires. The years of unilateral CI use were the reason for the inferior
results in the UCI/SeqBiCI group. One year after receiving CI2, the UCI/seqBiCI group
performance did not statistically differ from the performance of the simBiCI group on all
these outcomes. Furthermore, no longitudinal differences were seen in tinnitus burden
prevalence between groups. Finally, the complications that occurred during this trial
were infection, dysfunction of CI, facial nerve palsy, tinnitus and vertigo.
Conclusion: This randomized controlled trial on bilaterally severely hearing impaired
participants found a significantly worse longitudinal performance of UCI/seqBiCI
compared to simBiCI on multiple behavioral and self-reported outcomes regarding
speech perception in noise and localization abilities. This difference is associated with
the inferior performance of the UCI/seqBiCI participants during the years of unilateral CI
use. After receiving the second CI however, the performance of the UCI/seqBiCI group
did not significantly differ from the simBiCI group.
Trial Registration: Dutch Trial Register NTR1722.
Keywords: bilateral cochlear implantation, sequential, simultaneous, bimodal, QoL, RCT
INTRODUCTION
Binaural hearing enables a person to differentiate a sound
of interest from background noise and localize sounds by
using various effects of binaural hearing such as: summation,
head shadow, and squelch effect (Dirks, 1969; MacKeith, 1971;
Bronkhorst, 1988; Middlebrooks and Green, 1991). There is
a wealth of scientific evidence advocating bilateral cochlear
implantation (BiCI) over unilateral cochlear implantation (UCI),
highlighting that input in both ears instead of one holds
evident advantages. In recent years, the difference between
BiCI and UCI in adults with severe-to-profound sensorineural
hearing loss (SNHL) has been studied thoroughly (Crathorne
et al., 2012; Gaylor et al., 2013; van Schoonhoven et al.,
2013) evidencing a benefit of BiCI over UCI on speech
perception tasks in noise, localization of sounds abilities
and quality of hearing (QoH) and quality of life (QoL)
improvement. Nonetheless, we believe that a lack of high level
concrete evidence such as that derived from a randomized
controlled trial (RCT) is much needed to elucidate the
BiCI advantage over UCI. Many health care systems such
as that in the Netherlands do not reimburse the second
cochlear implant in adults due to insufficient proof of societal
benefit (cost-utility).
Thus far, there is a lack of overall consensus on whether
bilateral cochlear implants should be implanted simultaneously
or sequentially. Observational studies have demonstrated
advantages of simultaneous BiCI (simBiCI) over UCI
as well as sequential BiCI (seqBiCI) over UCI, but no
comparative studies exist on the difference between simBiCI
versus seqBiCI.
In 2016, our research group published the first results
of a RCT comparing outcomes of BiCI to UCI (with or
without contralateral hearing aid (HA), e.g., bimodal). It showed
conclusive evidence that BiCI patients have superior results over
UCI patients on speech perception in noise and localization
of sounds using various behavioral and self-reported outcome
measures (Smulders et al., 2016; van Zon et al., 2016). UCI
patients in that study received a second CI after 2 years of
unilateral CI use, enabling researchers to not only investigate
the difference between BiCI and UCI (and bimodal), but also
evaluate performances between simultaneous BiCI (simBiCI) and
sequential BiCI (UCI/BiCI). The results of this cross-sectional
comparison demonstrated comparable performances in both
groups for almost all outcome measures after 1 year of BiCI
experience (Kraaijenga et al., 2017).
It has been reported that short and long-term performance of
CI recipients often varies. To date, investigations evaluating long-
term outcomes after simBiCI compared with seqBiCI in adult
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patients are lacking. In the current paper, we present long-term
results of 4 years of follow-up using longitudinal analyses
that evaluates behavioral outcomes (speech perception and
localization), self-reported outcomes (QoL, QoH, and tinnitus
outcomes), as well as complications that occurred during the
course of this trial.
MATERIALS AND METHODS
Ethical Considerations
This study was approved by the Human Ethics Committees
of the Academic Medical Center Amsterdam and consecutively
tested for local applicability at all participating centers (University
Medical Centers of Utrecht, Maastricht, Nijmegen, Leiden, and
Groningen) (NL2466001808), registered in the Dutch Trial
Register (NTR1722) and conducted according to the Declaration
of Helsinki. Written informed consent was obtained from
all participants (Smulders et al., 2016; van Zon et al., 2016;
Kraaijenga et al., 2017).
Study Design and Participants
This RCT compares behavioral and self-reported outcomes
of simBiCI to seqBiCI (UCI/seqBiCI group) in adults with
severe-to-profound bilateral postlingual SNHL longitudinally
during a 4-year follow-up. Data were reported according to the
CONSORT statement (Schulz et al., 2010).
Between December 2009 and September 2012, all adults
eligible for cochlear implantation by the clinical teams of
University Medical Centers Utrecht, Maastricht, Nijmegen,
Groningen, and Leiden were assessed for this study’s inclusion
and exclusion criteria (Smulders et al., 2016; van Zon et al., 2016;
Kraaijenga et al., 2017). The inclusion criteria were: age: 18–
70 years; postlingual onset of SNHL; unaided pure-tone average
(PTA, mean of 500, 1,000, 2,000 Hertz) ≥70 dB in both ears;
duration of severe-to-profound SNHL < 20 years in each ear
and a difference in duration of deafness between both ears < 10
years; marginal benefit of HAs, defined as an aided consonant
vowel consonant (CVC) phoneme score for both ears of ≤50%
at 65 dB sound pressure level (SPL); Dutch as native language;
willingness and ability to participate in all scheduled procedures;
general health allowing general anesthesia for the duration
of potential simBiCI; Dutch health insurance coverage; and
agreement to be implanted with Advanced Bionics R© implants.
The exclusion criteria were: previous CI; abnormal cochlear
anatomy; and chronic ear infections; van Zon et al., 2016;
Kraaijenga et al., 2017).
Intervention
After giving written informed consent and undergoing baseline
evaluations, patients were randomly allocated to simBiCI or
seqBiCI (UCI/seqBiCI group). It is important to note that in
the Netherlands, BiCI is not yet reimbursed in adults. The
UCI/seqBiCI group had an inter-implant interval of 2 years
(Figure 1). Using a web-based randomization program, a
block randomization per center strategy was used to obtain
an equal distribution between simBiCI and UCI/seqBiCI
groups in all centers (Smulders et al., 2016; van Zon et al.,
2016; Kraaijenga et al., 2017). All participants received an
Advanced Bionics HiRes90K R© implant (Advanced Bionics,
Sylmar, CA, United States) coupled with a Harmony
processor with HiRes/HiRes120 processing strategies.
Participants in the UCI/seqBiCI group were encouraged to
keep using a contralateral HA in the first 2 years before
sequential implantation.
Follow-Up
All outcome measures, unless otherwise mentioned below, were
evaluated at baseline and after 1, 2, 3, and 4 years of follow-
up (Figure 1). The follow up visits lasting approximately 2–
2.5 h entailed filling respective questionnaires and behavioral
testing. Participants and observers were not blinded for
the intervention during evaluations due to the nature of
the intervention.
Behavioral Outcome Measures
Behavioral outcomes included speech perception in noise coming
from a source directly in front of the patient (speech and
noise from a target located in front of the listener at 0 degrees
azimuth), speech intelligibility-in-noise from spatially separated
sources (SISSS), localization capabilities and speech perception
in quiet. All behavioral outcomes were conducted using the
AB-York Crescent of Sound set-up, with horizontally placed
loudspeakers in a semicircle around the participant (Smulders
et al., 2015). Numbers representing the loudspeaker were shown
on monitors below the loudspeakers. In the UCI/seqBiCI
group, data were obtained from the ‘participant’s preferred
situation’ for the tests conducted before the second implantation.
The preferred situation was determined as the situation in
which patients performed best, either using the CI (CI1) only
or the bimodal condition (CI1 + contralateral HA). In the
simBiCI group and for the latter two test moments in the
UCI/seqBiCI group, data were gathered from tests performed
with both cochlear implants switched on (Smulders et al., 2015;
Kraaijenga et al., 2016).
Speech Perception in Noise
The primary outcome was speech perception in noise coming
from a source directly in front of the patient, measured with
the Utrecht-Sentence Test with Adaptive Randomized Roving
levels. Dutch VU-98 were presented in noise at 65, 70, or 75 dB
SPL (randomly selected). The number of keywords correctly
repeated per sentence was scored. Sentences were presented with
an initial signal-to-noise ratio (SNR) of +20 dB. If a sentence
was scored correct (2 of 3 or 3 of 5 keywords correct), the
SNR of the next sentence was decreased by increasing the
noise level. Contrarily, if a sentence was scored as incorrect,
the SNR was increased. The SNR was altered in steps of 10,
5 and 2.5 dB. The mean SNR of the last 10 sentences was
calculated, resulting in a speech reception threshold in noise
(SRTn) (Smulders et al., 2015, 2016; Kraaijenga et al., 2016).
A lower score reflects better speech perception. An SRTn of
30 dB was considered speech perception in relative silence
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FIGURE 1 | Flowchart of enrollment. simBiCI, simultaneous bilateral cochlear implantation; UCI/seqBiCI, unilateral/sequential bilateral cochlear implantation.
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and was used as a cut-off point for all scores above 30 dB
(Kraaijenga et al., 2016).
In the SISSS, also resulting in an SRTn, sentences were
presented from 60◦ azimuth to the left of the patient and noise
from 60◦ azimuth to the right of the patient (S-60 N+60) and
vice versa (S+60 N-60) (Kraaijenga et al., 2016). When sounds
come from different directions, participants usually have a best
performance situation (BPS) and a worst performance situation
(WPS). A participant’s BPS was determined as the situation where
speech was presented to the ear with the lowest SNR and noise
to the ear with the highest SNR. In a participant’s WPS, speech
and noise originate from the opposite sides. In the UCI/seqBiCI
group before CI2, the BPS was defined as the situation in which
the target speech was presented to the implanted ear and noise
to the non-implanted ear (Kraaijenga et al., 2016, 2017; Smulders
et al., 2016; van Zon et al., 2016).
Localization Capabilities
For the localization test, participants were instructed to look
at the loudspeaker placed directly in front during the entire
procedure. A camera was placed in front of the participant and
a deviation of the head of the participant was corrected by
the observer. Thirty short phrases (“Hello, what’s this?”) were
presented randomly at 60, 65, or 70 dB SPL from one of the
loudspeakers. The results were percentage of correct responses.
The test was performed in three localization conditions: 15◦
angle azimuth between five loudspeakers, 30◦ angle azimuth
between five loudspeakers, and 60◦ angle azimuth between
three loudspeakers (Smulders et al., 2016; van Zon et al., 2016;
Kraaijenga et al., 2017).
Speech Perception in Quiet
Speech perception in quiet from a loudspeaker in front of
the patient was measured using the standard Dutch CVC test,
resulting in a maximum percentage correctly repeated phonemes.
This was the only behavioral test which was evaluated at baseline,
before randomization.
Self-Reported Outcome Measures
Quality of Life
The QoL questionnaires included the EuroQol five-dimensional
questionnaire (EQ-5D), the Health Utilities Index mark 3
(HUI3), a Visual Analog Scale (VAS) on general health, and the
Time Trade-off (TTO) (Torrance, 1986; EuroQol Group, 1990;
Feeny et al., 2002; Lamers et al., 2005). The EQ-5D contains a
thermometer indicating general health state and five dimensions
of QoL: mobility, self-care, usual activities, pain/discomfort and
anxiety/depression. The result is a single index value for health
status: a utility score ranging from −0.33 to 1.00 (EuroQol
Group, 1990; Lamers et al., 2005; Ramakers et al., 2016). The
HUI3 consists of eight elements of health status. The result
is a utility score between −0.36 and 1.00 (Feeny et al., 2002;
Ramakers et al., 2016). The VAS on general health contains a
thermometer for general QoL, which results in a utility score
between 0 and 1 (Ramakers et al., 2016). The TTO is an
instrument asking participants whether they are willing to trade
expected life years for perfect hearing. The utility is calculated as:
utility = (life expectancy – number of years a participant would
trade)/life expectancy (Smulders et al., 2016). This question
needs good instruction, therefore, it was decided not to let
participants answer it independently preoperatively. However,
at the 1-,2-,3- and 4-year follow-up moments this information
was gathered. For all QoL outcomes, a higher score reflects a
better QoL.
Quality of Hearing
The QoH questionnaires included the VAS on hearing, the
Speech, Spatial and Qualities of Hearing Scale (SSQ) and the
Nijmegen Cochlear Implant Questionnaire (NCIQ) (Hinderink
et al., 2000; Gatehouse and Noble, 2004). The VAS on hearing
contains a thermometer for hearing, which results in a score
between 0 and 1 (Ramakers et al., 2016). The SSQ consists of
three subdomains. The SSQ1 comprises questions on speech
understanding in quiet, in background noise, in reverberant
environments and on the telephone. The SSQ2 comprises
questions on spatial hearing; identifying directions of sounds
and distance approximation, and the SSQ3 comprises questions
on the QoH (Gatehouse and Noble, 2004). The results are
three subdomain scores ranging from 0 to 10 (Gatehouse and
Noble, 2004; Ramakers et al., 2017b). The NCIQ contains
six subdomains of hearing: (1) Basic sound perception, (2)
Advanced sound perception (in difficult daily listening situations
or background noise), (3) Speech production, (4) Self-esteem,
(5) Activity limitations, (6) Social interaction (Hinderink et al.,
2000). The results are subdomain scores ranging from 0 to
100 (Hinderink et al., 2000; Ramakers et al., 2017b). As this
questionnaire is specifically designed for the evaluation after
cochlear implantation, this questionnaire was not administered
at baseline. For all QoH outcomes, a higher score reflects a
greater ability.
Tinnitus
The tinnitus questionnaires included the Tinnitus Handicap
Inventory (THI) and Tinnitus Questionnaire (TQ) (Newman
et al., 1996; McCombe et al., 2001). The THI is a questionnaire
regarding tinnitus handicap in daily life. The questionnaire
comprises a 12-item functional subscale, an 8-item emotional
subscale and a 5-item catastrophic subscale (Newman et al.,
1996; McCombe et al., 2001; Ramakers et al., 2017a). The
TQ consists of 52 questions on emotional and cognitive
distress, intrusiveness, auditory perceptual difficulties,
sleep disturbance and somatic complaints (Meeus et al.,
2007). Both tinnitus questionnaires were administered to all
participants, but could only be completed when a participant
experienced tinnitus.
Sample Size Calculation
Sample size was calculated before the start of the trial using
a T-test analysis of the primary outcome measure. Fourteen
participants in each group were needed to detect a clinically
relevant difference of 3 dB in SRTn between groups on the
speech perception-in-noise coming from a source in front of
the participant test with a standard deviation of 3 dB, an alpha
of 0.05 and a power of 80%. Five additional subjects were
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included per group to compensate for any potential unexpected
loss to follow-up (Smulders et al., 2016; van Zon et al., 2016;
Kraaijenga et al., 2017).
Missing Data and Loss to Follow-Up
In case participants were lost to follow-up, analyses were
performed with (intention to treat) and without these missing
data as a sensitivity analysis.
Statistical Analysis
Prior to analysis, all data were double-checked by two researchers
independently. Patient characteristics were presented as counts,
percentages, and medians with interquartile ranges (IQRs).
All outcome measures were analyzed longitudinally (follow-
up points 1, 2, 3, and 4 years) via a linear regression
analysis with an autoregressive residual covariance matrix
(generalized estimating equations type, using a maximum
likelihood estimation method). The tinnitus outcomes were
analyzed longitudinally via a logistic regression analysis with an
autoregressive residual covariance matrix (generalized estimating
equations type), as the outcome was dichotomized: the presence
of tinnitus burden (yes or no). A participant was considered
to experience tinnitus burden when a score higher than 0 was
reached on either of the questionnaires.
All models included time (as a categorical variable), group
(simBiCI versus UCI/seqBiCI), the interaction between time and
group (to study whether the course of scores differed between the
study groups) and baseline score of the particular outcome (to
adjust for possible baseline differences). Since the TTO and NCIQ
were not administered at baseline, the VAS on health and VAS
on hearing scores were used as baseline scores. For the speech
perception-in-noise and localization tests the CVC phoneme
score was used. HA use (yes/no) at baseline (before the study)
was the only variable which differed significantly between groups
(Smulders et al., 2016; van Zon et al., 2016; Kraaijenga et al.,
2017) and for that reason, this variable was added to all models
to verify whether it was a possible confounder. Sex and age may
have been related to some of the outcomes discussed in this
manuscript. If so, sex and age would have also been related to the
baseline outcomes. Since we corrected for baseline outcomes, no
additional corrections for sex and age were performed. Residuals
of the final linear models were checked for normality and showed
a normal distribution. To visualize the course of all behavioral
and self-reported outcomes for both study groups, all outcome
measures were graphed, presenting mean outcome values with
standard deviations.
A p-value < 0.05 was considered statistically significant. The
regression models were generated in SPSS version 22.0 whereas
the residue analyses were performed in SAS version 9.4.
TABLE 1 | Characteristics of participants at time of inclusion in the study.
UCI/SeqBiCI Median [IQR] SimBiCI Median [IQR]
Male:Female 11:08 08:11
Age at inclusion (years) 54 [43–64] 52 [36–63]
Duration of severe HL AD (years) 17 [9–33] 16 [11–25]
Duration of severe HL AS (years) 18 [9–35] 16 [11–25]
First CI, right:left 6:13 17:2
PTA AD (dB) 106 [94–111] 106 [89–119]
PTA AS (dB) 108 [93–114] 108 89–120]
CVC phoneme score with hearing aids (%) 44 [29–56] 48 [24–63]
Hearing aid use year 0, yes:no 19:0 15:4
Hearing aid use year 1, yes:no 12:7 Not applicable
Hearing aid use year 2, yes:no 13:5 (1 LTFU) Not applicable
Treatment hospital
Utrecht 11 8
Maastricht 4 5
Nijmegen 2 3
Leiden 1 2
Groningen 1 1
Cause of deafness
Hereditary 7 9
Unknown and progressive 9 6
Sudden deafness 0 2
Head trauma 0 1
Meningitis 2 0
Rhesus antagonism 1 0
Sound exposure 0 1
BiCI, bilateral cochlear implantation; yrs, years; UCI, unilateral cochlear implantation; Sim, simultaneous; Seq, sequential; AD, auricus dexter; AS, auriculus sinistra; PTA,
pure tone average over 1, 2, and 4 kilohertz; CVC, consonant vowel consonant; CI, cochlear implant; LTFU, lost to follow-up; Hz, hertz; IQR, interquartile ranges.
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RESULTS
Participant Characteristics
Between December 2009 and September 2012, 512 patients
were assessed for eligibility. Forty participants were randomized
and 19 participants were included in each group (Figure 1).
Characteristics of participants are described in Table 1 (Smulders
et al., 2016; van Zon et al., 2016; Kraaijenga et al., 2017). As
previously mentioned, the groups were similar at baseline except
for the number of participants using a HA (19 vs. 15).
Missing Data and Loss to Follow-Up
During the second and third year of follow-up, two participants
in the UCI/seqBiCI group withdrew for personal reasons. A third
participant was excluded from the UCI/seqBiCI group because
of poor performance with the first implant. This participant
appeared to have a hearing loss due to rhesus antagonism and was
expected not to benefit from a second CI because of this central
cause of deafness (Figure 1) (Smulders et al., 2016; van Zon et al.,
2016; Kraaijenga et al., 2017).
At year 1, the 15◦ localization results were missing in one
participant in the simBiCI group. A cut-off of 30 dB for speech
perception scores was used for one participant in each group. At
year 3, the results of the VAS health and hearing were missing in
one participant in the simBiCI group and the TTO was missing
for another participant in this group. At year 4, the EQ-5D was
missing for one participant in the simBiCI group and TTO was
missing for another participant in this group.
Behavioral Outcomes
Figure 2 shows all behavioral outcomes during the 4 years
follow-up for both study groups. Group differences, course
FIGURE 2 | Behavioral outcomes on hearing: a 4-year follow-up. Scores are presented in mean values with an error bar representing the standard deviation. SISSS,
speech intelligibility-in-noise from spatially separated sources; WPS, worst performance situation; BPS, best performance situation; CVC, consonant vowel
consonant; yr, year; CI, cochlear implant; SimBiCI, simultaneous bilateral cochlear implantation; UCI/seqBiCI, unilateral cochlear implantation/sequential bilateral
cochlear implantation group. To improve readability, the results of both groups are presented interleaved, yet follow-up moments were similar in both groups.
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TABLE 2 | Results from a linear regression analysis with an autoregressive residual covariance matrix (generalized estimating equations type) for all objective outcomes.
Parameter Mean SD Lower bound 95% CI Upper bound 95% CI P-value
Speech perception in noise from directly in front (dB) Treatment 1.99 1.77 −1.55 5.53 0.265
Year 2 0.49 1.22 −1.91 2.91 0.686
Year 3 −0.38 1.05 −2.45 1.69 0.718
Year 4 −0.81 0.80 −2.41 0.78 0.314
Seq × year 2 −0.18 1.74 −3.63 3.26 0.916
Seq × year 3 −0.23 1.51 −3.23 2.76 0.877
Seq × year 4 0.02 1.16 −2.27 2.32 0.986
CVC baseline −0.06 0.03 −0.12 0.01 0.076
SISSS: WPS (dB) Treatment 8.70 2.37 3.96 13.44 <0.001
Year 2 1.51 1.76 −1.97 4.99 0.391
Year 3 −0.41 1.53 −3.43 2.61 0.787
Year 4 −0.58 1.19 −2.94 1.77 0.623
Seq × year 2 −1.50 2.51 −6.47 3.47 0.551
Seq × year 3 −6.83 2.21 −11.20 −2.45 0.002
Seq × year 4 −7.06 1.71 −10.44 −3.67 <0.0001
CVC baseline −0.07 0.04 −0.15 0.02 0.113
SISSS: BPS (dB) Treatment 0.79 1.96 −3.14 4.72 0.688
Year 2 −1.07 1.40 −3.84 1.70 0.447
Year 3 −2.60 1.22 −5.01 0.19 0.035
Year 4 −2.68 0.95 −4.56 −0.80 0.006
Seq × year 2 0.34 2.00 −3.62 4.29 0.866
Seq × year 3 0.48 1.76 −3.01 3.97 0.786
Seq × year 4 0.60 1.37 −3.31 2.11 0.663
CVC baseline −0.012 0.04 −0.20 −0.03 0.009
HA use 7.05 3.42 0.10 14.00 0.047
Localization, 15◦ (% correct) Treatment −27.87 5.01 −37.80 −17.94 <0.0001
Year 2 −3.98 4.81 −13.50 5.54 0.410
Year 3 3.21 4.54 −5.77 12.19 0.481
Year 4 9.09 3.96 1.23 16.94 0.024
Seq × year 2 1.12 6.82 −12.39 14.60 0.870
Seq × year 3 19.64 6.53 6.72 32.56 0.003
Seq × year 4 17.85 5.63 6.69 29.01 0.002
CVC baseline 0.05 0.07 −0.09 0.19 0.493
Localization, 30◦ (% correct) Treatment −41.09 4.56 −50.12 −32.06 <0.0001
Year 2 −5.45 4.36 −14.06 3.16 0.213
Year 3 −1.53 4.09 −9.63 6.56 0.709
Year 4 −2.25 3.53 −9.27 4.77 0.526
Seq × year 2 3.24 6.21 −9.02 15.51 0.602
Seq × year 3 34.20 5.93 22.48 45.92 <0.0001
Seq × year 4 35.73 5.07 25.67 45.79 <0.0001
CVC baseline 0.01 0.07 −0.12 0.14 0.905
Localization, 60◦ (% correct) Treatment −44.45 3.88 −52.15 −36.74 <0.0001
Year 2 −0.35 3.66 −7.58 6.87 0.923
Year 3 1.23 3.40 −5.50 7.96 0.719
Year 4 −0.13 2.89 −5.89 5.62 0.963
Seq × year 2 −1.37 5.21 −11.67 8.93 0.793
Seq × year 3 38.26 4.93 28.52 – 48.01 <0.0001
Seq × year 4 43.04 4.15 34.78 – 51.29 <0.0001
CVC baseline 0.14 0.06 0.02 – 0.26 0.020
CVC score (%) Treatment −3.72 3.34 −10.33 – 2.88 0.267
Year 2 −1.47 3.34 −8.07 – 5.12 0.659
Year 3 1.79 3.34 −4.81 – 8.39 0.536
Year 4 2.24 3.44 −4.54 – 9.04 0.514
(Continued)
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TABLE 2 | Continued
Parameter Mean SD Lower bound 95% CI Upper bound 95% CI P-value
Seq × year 2 3.56 4.75 −5.84 – 12.95 0.455
Seq × year 3 2.14 4.83 −7.40 – 11.69 0.658
Seq × year 4 −0.13 4.90 −9.81 – 9.55 0.979
CVC baseline 0.14 0.04 0.06 – 0.21 <0.001
Reference treatment group = simBiCI; reference year = year 1. The final model contained the following variables: time + treatment + time × treatment + baseline CVC
phoneme score. In case there was a confounding role for hearing aid use at baseline, this variable was included in the final model as well. SISSS, speech intelligibility-in-
noise from spatially separated sources; CVC, consonant vowel consonant; HA, hearing aid; SimBiCI, simultaneous bilateral cochlear implantation; seq, unilateral cochlear
implantation/sequential bilateral cochlear implantation group. Bold value means statistical significance.
per group and difference between follow-up moments
per group were analyzed using the previously mentioned
linear regression analysis with an autoregressive residual
covariance matrix. In the UCI/seqBiCI group, 10 and 11
out of 16 participants used a contralateral HA at year 1 and
year 2 respectively.
Speech Perception in Noise
Speech perception in noise coming from a source in front of
the participant did not differ significantly between UCI/seqBiCI
and simBiCI over time (1.99 dB [−1.55 – 5.53], p = 0.265)
(Table 2). The course of the SRTn did not differ significantly
between the two groups and for both groups the SRTns remained
stable over time.
In the WPS of the SISSS test, the UCI/seqBiCI group
performed significantly worse over time: 8.70 dB [3.96 –
13.44], p < 0.001. A significant improvement was seen in
the UCI/seqBiCI group after receiving CI2 (year 3 (seqBiCI)
vs. year 1 (UCI); −6.83 dB [−11.20 – −2.45], p = 0.002).
In the BPS of the SISSS test however, no difference between
groups over time was found, yet a significant improvement
was seen in the simBiCI group after years 3 and 4 compared
to year 1 (year 4 vs. year 1: −2.68 dB [−4.56 – −0.80],
p = 0.006). HA use at baseline was a significant confounder
for the SISSS BPS, and therefore the final model was corrected
for HA use.
Localization
The largest differences between groups were seen on the
localization tests over time, for example in the 60 degrees
configuration: the scores of UCI/seqBiCI were significantly
lower (−44.45% [−52.15 – −36.74], p < 0.0001) than the
scores of the simBiCI group over time. The UCI/seqBiCI
group showed a significant improvement after receiving
CI2, which is most evident between year 4 and year 1:
43.04% [34.78 – 51.29], p < 0.0001. The direction and
significance of the results of the localization tests in 15
and 30 degrees configurations did not differ from the 60
degrees results.
Speech Perception in Quiet
The CVC phoneme scores did not differ significantly between
groups over time. Also, the course of these scores did not differ
significantly between groups and for both groups the scores were
stable over time.
Self-Reported Outcomes
Quality of Life Outcomes
Figure 3 shows the QoL outcomes preoperatively and during the
4 years of follow-up for both study groups. The EQ-5D, HUI3
and VAS general health scores did not differ significantly between
the UCI/seqBiCI and simBiCI group over time (Table 3). Also
the course of these scores did not differ between groups and for
both groups the EQ-5D, HUI3 and VAS general scores remained
stable over time.
The TTO score was significantly lower in the UCI/seqBiCI
group compared with the simBiCI group over time (−0.078
[−0.140 – −0.017], p = 0.017). A significant improvement was
seen in the UCI/seqBiCI group after receiving CI2 (year 3 vs.
year 1: 0.084 [0.003- 0.165], p = 0.017). HA use was a significant
confounder for the HUI3, and therefore the final model was
corrected for HA use.
Quality of Hearing Outcomes
Figure 4 shows the QoH outcomes preoperatively and
during the 4 years of follow-up for both study groups.
The VAS hearing scores differed significantly between
the UCI/seqBiCI and simBiCI group over time (−0.12
[−0.24 – −0.01], p = 0.036) (Table 4). The course of
these scores did not differ between groups. The scores in
the UCI/seqBiCI group did not improve significantly after
receiving CI2.
The SSQ1, SSQ2 and SSQ3 scores were significantly lower
in the UCI/seqBiCI group compared with the simBiCI group
over time (most evident for SSQ2: −2.32 [−3.38 – −1.26],
p ≤ 0.001). A significant improvement was seen in the
UCI/seqBiCI group after receiving CI2 for the SSQ1 (year
4 vs. year 1: 0.75 [0.10 – 1.41], p = 0.025) and the SSQ
2 and 3 (years 3 and 4 vs. year 1, for example year 3
vs. year 1 for SSQ2: 1.82 [0.60 – 3.04], p = 0.004). In the
simBiCI group, all SSQ scores remained stable in the 4 years
of follow-up.
The social interaction score of the NCIQ was significantly
lower in the UCI/seqBiCI group compared with the simBiCI
group over time (−9.26 [−18.20 –−0.33], p = 0.042). Significant
increases in basic sound perception, self-esteem, activity and
social interaction scores were seen in the seqBiCI group after
receiving CI2 (year 4 vs. year 1, most evident for basic
sound perception: 12.22 [4.27 – 20.17], p = 0.003). In the
simBiCI group, all NCIQ scores remained stable in the 4 years
of follow-up.
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FIGURE 3 | Self-reported outcomes on quality of life: a 4-year follow-up. Scores are presented in mean values with an error bar representing the standard deviation.
EQ5D, Dutch EuroQol-5D; HUI3, Health Utilities Index 3; VAS, Visual Analog Scale; TTO, Time Trade-off; yr, year; CI, cochlear implant; SimBiCI, simultaneous
bilateral cochlear implantation; UCI/seqBiCI, unilateral cochlear implantation/sequential bilateral cochlear implantation group. To improve readability, the results of
both groups are presented interleaved, yet follow-up moments were similar in both groups.
Tinnitus Outcomes
Figure 5 shows the prevalence of tinnitus burden preoperatively
and during the 4 years of follow-up for both study groups.
Although the prevalence appears larger in de simBiCI group,
the prevalence of tinnitus burden, corrected for baseline
prevalence, did not differ significantly between the UCI/seqBiCI
and simBiCI group over time. Also the course of tinnitus
burden did not differ between groups and for both groups the
presence of tinnitus burden remained stable in the 4 years of
follow-up (Table 5).
Sensitivity Analysis
A sensitivity analysis of the behavioral and self-reported
data without participants with missing data revealed no
differences regarding direction, effect sizes or significance
of the results compared to the primary analysis except
for the NCIQ basic sound perception: a significant overall
lower NCIQ basic sound perception score was seen in
the UCI/seqBiCI group (−11.61, p: 0.028). This indicates
that missing data in the original analyses did not obscure
the results.
Complications
As shown in Table 6, several complications occurred during the
4 years follow-up period. One participant suffered from vertigo
1 year following simBiCI. Electronystagmographic examination
was inconclusive, yet vestibular areflexia was excluded as the
cause of vertigo. In one participant in the UCI/seqBiCI group,
the left CI had to be explanted and re-implanted 4 years after
initial implantation. After initial good performance, the left
CI became dysfunctional resulting in an increased stimulation
level and coexisting facial nerve stimulation. The cause of
this failure remained unclear, imaging and integrity tests were
normal. One participant in the simBiCI group with a history
of panhypopituitarism, hypothyroidism, kidney failure and
systemic lupus erythematosus for which corticosteroids were
used, suffered from skin flap necrosis after implantation of the left
CI. Surgery was needed to close the subsequent skin defect. One
participant suffered from a facial nerve palsy 10 days after seqBiCI
(House Brackmann grade 3), of unknown origin, possibly due
to a viral infection. The palsy improved spontaneously to House
Brackmann grade 2. Another participant in the UCI/seqBiCI
group suffered from acute otitis media in the secondly implanted
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TABLE 3 | Results from a linear regression analysis with an autoregressive residual covariance matrix (generalized estimating equations type) for quality of life outcomes.
Parameter Mean Standard deviation Lower bound 95% CI Upper bound 95% CI P-value
EQ-5D Treatment 0.023 0.031 −0.038 0.083 0.459
Year 2 0.020 0.030 −0.038 0.079 0.495
Year 3 0.023 0.028 −0.033 0.079 0.425
Year 4 0.034 0.025 −0.016 0.083 0.178
Seq × year 2 −0.009 0.042 −0.093 0.074 0.825
Seq × year 3 −0.021 0.041 −0.102 0.061 0.618
Seq × year 4 −0.038 0.036 −0.108 0.033 0.296
EQ-5D baseline 0.688 0.097 0.493 0.883 <0.0001
HUI3 Treatment −0.011 0.050 −0.112 0.089 0.821
Year 2 0.030 0.046 −0.060 0.120 0.510
Year 3 0.005 0.042 −0.079 0.088 0.911
Year 4 −0.022 0.035 −0.090 0.046 0.525
Seq × year 2 −0.034 0.065 −0.162 0.095 0.603
Seq × year 3 0.012 0.061 −0.109 0.133 0.848
Seq × year 4 0.019 0.050 −0.081 0.119 0.711
HUI3 baseline 0.520 0.164 0.189 0.850 0.003
HA use −0.172 0.068 −0.308 −0.036 0.014
VAS health Treatment 0.053 0.040 −0.026 0.132 0.186
Year 2 0.030 0.035 −0.039 0.099 0.394
Year 3 0.048 0.032 −0.015 0.112 0.135
Year 4 −0.012 0.025 −0.062 0.038 0.647
Seq × year 2 −0.021 0.050 −0.120 0.078 0.672
Seq × year 3 −0.062 0.046 −0.154 0.029 0.179
Seq × year 4 0.053 0.037 −0.020 0.126 0.155
VAS health baseline 0.210 0.077 0.054 0.365 0.009
TTO Treatment −0.078 0.031 −0.140 −0.017 0.013
Year 2 −0.002 0.030 −0.061 0.057 0.958
Year 3 −0.040 0.029 −0.096 0.017 0.169
Year 4 −0.012 0.024 −0.060 0.036 0.627
Seq × year 2 −0.005 0.043 −0.089 0.079 0.913
Seq × year 3 0.084 0.041 0.003 0.165 0.043
Seq × year 4 0.047 0.035 −0.023 0.117 0.183
VAS health baseline 0.124 0.053 0.017 0.231 0.025
Reference treatment group = simBiCI. Reference year = year 1. The final model contained the following variables: time + treatment + time × treatment + baseline score.
In case there was a confounding role for hearing aid use at baseline, this variable was included in the final model as well. EQ-5D, EuroQol five-dimensional questionnaire;
HUI3, the Health Utilities Index mark 3; HA, hearing aid; VAS, Visual Analog Scale on general health; TTO, Time Trade-off; SimBiCI, simultaneous bilateral cochlear
implantation; seq, unilateral cochlear implantation/sequential bilateral cochlear implantation group. Bold value means statistical significance.
ear for which intravenous antibiotic treatment was needed. One
participant in the UCI/seqBiCI group perceived extra sound
sensations in CI2. In one participant in the UCI/seqBiCI group,
local antibiotics had to be administered to treat a skin infection at
the implantation site. In both groups, a participant experienced
pain at the ear’s helix due to pressure of the speech processor, for
which a support frame and a body worn speech processor were
provided. Although it appears that the complication rate is higher
in de UCI/seqBiCI group, this was not statistically supported.
DISCUSSION
Key Findings
The current RCT evaluated the longitudinal behavioral and self-
reported outcomes after simBiCI compared with UCI/seqBiCI,
with a 2-year inter-implant interval, in adult patients with
severe-to-profound bilateral SNHL with marginal benefit
of conventional HAs (an aided CVC phoneme score of
≤50% at 65 dB SPL).
Three participants allocated to the UCI/seqBiCI group, did not
proceed to seqBiCI. This study showed that speech perception
in noise, localization abilities (SISSS WPS, localization) and self-
reported results (SSQ 1 and 2) were significantly worse in the
UCI/seqBiCI group compared to the simBiCI group over the
course of the 4-year follow-up. This is associated with the poorer
results obtained by the UCI/seqBiCI group in the first 2 years
of unilateral CI use. In the UCI/seqBiCI group, a significant
improvement of these scores was seen after receiving CI2. With
this improvement, the UCI/seqBiCI participants (with 2 years
of bilateral experience) reached the same level as the simBiCI
participants at 3 and 4 years of follow-up.
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FIGURE 4 | Self-reported outcomes on quality of hearing: a 4-year follow-up. Scores are presented in mean values with an error bar representing the standard
deviation. VAS, Visual Analog Scale; SSQ, Speech, Spatial and Qualities Hearing Scale; NCIQ, Nijmegen Cochlear Implant Questionnaire; yr, year; CI, cochlear
implant; SimBiCI, simultaneous bilateral cochlear implantation; UCI/seqBiCI, unilateral cochlear implantation/sequential bilateral cochlear implantation group. To
improve readability, the results of both groups are presented interleaved, yet follow-up moments were similar in both groups.
In one of four QoL questionnaires (TTO), a significantly
lower utility score was found in the UCI/seqBiCI group
compared to the simBiCI group over time. After the participants
received CI2 in the seqBiCI group, their TTO results reached
to the level of the simBiCI group. The prevalence of
tinnitus burden did not differ significantly between both
groups over time.
Comparison With Literature and Clinical
Implication
In previous publications from our group, studying the differences
between best performing situation with one CI (with or
without a contralateral HA) and simBiCI (Smulders et al.,
2016; van Zon et al., 2016), advantages of simBiCI over UCI
on spatial speech perception and localization of sounds were
demonstrated behaviorally and subjectively. Corresponding to
existing observational studies and our previous article from this
RCT, the present study identified that patients after seqBiCI also
benefit from receiving a second CI as demonstrated in the spatial
speech perception and localization of sounds tasks (Ramsden
et al., 2005; Summerfield et al., 2006; Zeitler et al., 2008; Olze
et al., 2012). Thus, this study shows that after providing deaf
patients with one CI, they still benefit from bilateral hearing
after sequentially implanting a second CI within an inter-implant
interval of 2 years.
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TABLE 4 | Results from a linear regression analysis with an autoregressive residual covariance matrix (generalized estimating equations type) for quality of hearing
outcomes.
Parameter Mean Standard deviation Lower bound 95% CI Upper bound 95% CI P-value
VAS hearing Treatment −0.122 0.057 −0.236 −0.008 0.036
Year 2 −0.029 0.052 −0.132 0.074 0.581
Year 3 −0.056 0.048 −0.152 0.040 0.249
Year 4 −0.050 0.039 −0.127 0.027 0.198
Seq × year 2 −0.028 0.075 −0.175 0.120 0.710
Seq × year 3 0.128 0.070 −0.010 0.266 0.069
Seq × year 4 0.107 0.056 −0.005 0.220 0.060
VAS hearing baseline 0.201 0.166 −0.132 0.534 0.232
SSQ1 Treatment −1.524 0.533 −2.591 −0.458 0.006
Year 2 0.161 0.356 −0.542 0.865 0.651
Year 3 −0.063 0.304 −0.665 0.538 0.835
Year 4 −0.183 0.225 −0.630 0.263 0.418
Seq × year 2 −0.409 0.508 −1.414 0.597 0.423
Seq × year 3 0.831 0.440 −0.041 1.703 0.062
Seq × year 4 0.750 0.330 0.096 1.405 0.025
SSQ1 baseline 0.984 0.220 0.540 1.429 <0.0001
SSQ2 Treatment −2.319 0.534 −3.380 −1.259 <0.0001
Year 2 0.460 0.472 −0.473 1.392 0.332
Year 3 0.357 0.426 −0.485 1.200 0.403
Year 4 0.291 0.336 −0.376 0.959 0.389
Seq × year 2 −0.999 0.673 −2.328 0.331 0.140
Seq × year 3 1.824 0.617 0.604 3.044 0.004
Seq × year 4 1.543 0.492 0.567 2.520 0.002
SSQ2 baseline 0.421 0.190 0.039 0.803 0.032
SSQ3 Treatment −1.623 0.550 −2.723 −0.523 0.005
Year 2 −0.288 0.401 −1.081 0.505 0.474
Year 3 −0.087 0.346 −0.772 0.598 0.802
Year 4 −0.229 0.259 −0.743 0.284 0.378
Seq × year 2 0.307 0.565 −0.811 1.425 0.588
Seq × year 3 1.051 0.494 0.072 2.029 0.036
Seq × year 4 1.205 0.374 0.463 1.947 0.002
SSQ3 baseline 0.473 0.161 0.146 0.800 0.006
NCIQ basic Treatment −9.620 5.315 −20.218 0.978 0.075
Year 2 −0.263 4.119 −8.406 7.879 0.949
Year 3 −1.316 3.601 −8.441 5.810 0.715
Year 4 −3.863 2.737 −9.292 1.565 0.161
Seq × year 2 −5.513 5.881 −17.139 6.112 0.350
Seq × year 3 6.352 5.216 −3.970 16.673 0.226
Seq × year 4 12.222 4.009 4.273 20.171 0.003
VAS hearing baseline −19.889 17.165 −54.545 14.767 0.253
NCIQ advanced Treatment −3.523 6.426 −16.391 9.345 0.586
Year 2 −0.376 4.049 −8.383 7.631 0.926
Year 3 0.764 3.456 −6.076 7.605 0.825
Year 4 −1.034 2.558 −6.106 4.038 0.687
Seq × year 2 −3.124 5.787 −14.569 8.322 0.590
Seq × year 3 2.485 5.006 −7.425 12.394 0.621
Seq × year 4 5.969 3.747 −1.460 13.398 0.114
VAS hearing baseline 7.293 21.821 −36.823 51.410 0.740
HA use −7.025 9.622 −26.485 12.436 0.470
NCIQ speech Treatment 0.680 4.581 −8.497 9.857 0.883
Year 2 −0.340 2.785 −5.848 5.168 0.903
Year 3 −0.559 2.368 −5.248 4.129 0.814
Year 4 −1.334 1.746 −4.796 2.128 0.447
(Continued)
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TABLE 4 | Continued
Parameter Mean Standard deviation Lower bound 95% CI Upper bound 95% CI P-value
Seq × year 2 −1.014 3.981 −8.888 6.861 0.799
Seq × year 3 −2.524 3.430 −9.316 4.267 0.463
Seq × year 4 −1.785 2.558 −6.856 3.286 0.487
VAS hearing baseline −29.738 15.691 −61.456 1.980 0.065
HA use −4.760 6.921 −18.754 9.234 0.496
NCIQ self esteem Treatment −6.806 4.844 −16.488 2.877 0.165
Year 2 −2.602 3.346 −9.218 4.013 0.438
Year 3 −2.635 2.873 −8.321 3.051 0.361
Year 4 −3.684 2.140 −7.928 0.559 0.088
Seq × year 2 0.713 4.781 −8.741 10.167 0.882
Seq × year 3 2.618 4.161 −5.618 10.855 0.530
Seq × year 4 7.084 3.135 0.869 13.299 0.026
VAS hearing baseline 10.330 16.380 −22.770 43.429 0.532
NCIQ activity Treatment −6.147 5.595 −17.338 5.044 0.276
Year 2 −0.150 3.796 −7.656 7.357 0.969
Year 3 −0.124 3.252 −6.562 6.313 0.970
Year 4 −2.476 2.417 −7.269 2.317 0.308
Seq × year 2 −1.719 5.425 −12.447 9.009 0.752
Seq × year 3 6.108 4.411 −3.217 15.433 0.197
Seq × year 4 7.802 3.540 0.783 14.822 0.030
VAS hearing baseline 18.473 19.026 −20.007 56.953 0.338
NCIQ social Treatment −9.264 4.471 −18.201 −0.327 0.042
Year 2 −0.804 3.149 −7.031 5.423 0.799
Year 3 0.157 2.711 −5.209 5.523 0.954
Year 4 1.308 2.025 −2.708 5.325 0.520
Seq × year 2 0.954 4.499 −7.943 9.850 0.832
Seq × year 3 5.790 3.927 −1.982 13.563 0.143
Seq × year 4 7.074 2.966 1.191 12.956 0.019
VAS hearing baseline 15.457 15.016 −14.913 45.827 0.310
Reference treatment group = simBiCI. Reference year = year 1. The final model contained the following variables: time + treatment + time × treatment + baseline score.
In case there was a confounding role for hearing aid use at baseline, this variable was included in the final model as well. VAS, Visual Analog Scale on hearing; SSQ,
Speech, Spatial and Qualities of Hearing Scale; NCIQ, Nijmegen Cochlear Implant Questionnaire; HA, hearing aid; SimBiCI, simultaneous bilateral cochlear implantation;
seq, unilateral cochlear implantation/sequential bilateral cochlear implantation group. Bold value means statistical significance.
No significant differences were found between simBiCI and
seqBiCI at 4 years follow-up on behavioral and self-reported
outcome measures tested. This finding does not advocate for
one of these implantation modalities over the other. Therefore,
when considering BiCI, individual factors that might influence
the choice for seqBiCI or simBiCI such as for example duration
of anesthesia, the intensive rehabilitation, as well as the cost-
effectiveness related with each intervention should be taken into
account. Yet, delaying implantation of the second ear in our
UCI/seqBiCI group did limit hearing in noise and localization
capabilities in the 2 years of unilateral CI use. This might have
real-life consequences in this timeframe. To our knowledge, the
present study is the first to compare outcomes of simBiCI versus
seqBiCI in an RCT.
The present findings encourage UCI patients with no or
marginal benefit from a contralateral HA to receive a second
CI in order to reach improved benefits in speech perception
in noise and localization abilities. Thus, there is evidence that
implant centers all over the world should consider seqBiCI for
all their unilaterally implanted patients with marginal effect or
no effect of a contralateral HA. Even though longer duration
of inter-implant interval is suggested to cause lesser benefit
of CI2 compared to CI1, multiple studies have shown that
bilateral results are better than unilateral results (Ramsden et al.,
2005; Zeitler et al., 2008). In the present study, the inter-
implant interval did not differ between participants in this trial,
therefore, the effect of duration of inter-implant interval was
not investigated.
It has already been shown that spatial speech perception
abilities continue to improve over time for at least 4
years after simBiCI (Eapen et al., 2009; Kraaijenga et al.,
2016). Longitudinal results of our study are in line
with these findings and show an increased performance
in the optimal situation of the SISSS in the simBiCI
group over time.
In this study, three participants did not proceed to seqBiCI
after UCI. Previous data suggested that not all UCI patients
proceed to seqBiCI (Foteff et al., 2016). Therefore, our study
finding may be a realistic representation of the actual clinical
population at various implant centers. Patients’ withdrawal
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FIGURE 5 | Tinnitus outcomes: a 4-year follow-up. The number of
participants with the presence of tinnitus burden. The presence of tinnitus
burden is defined as a score higher than 0 on either one of the questionnaires.
SimBiCI, simultaneous bilateral cochlear implantation; UCI/seqBiCI, unilateral
cochlear implantation/sequential bilateral cochlear implantation group.
might be influenced by good performance with CI1, yet
conversely, bad performance with CI1 could make patients
reluctant to proceed to seqBiCI. Of the three participants in
the UCI/seqBiCI group who did not proceed to seqBiCI, two
were happy with the results after UCI and one participant
who was deafened due to rhesus antagonism had such
poor results with UCI that improvement after seqBiCI
was not expected.
The lack of overall QoL improvement after seqBiCI
in three out of four QoL questionnaires corresponds to
earlier findings in literature (Summerfield et al., 2006). QoL
questionnaires are commonly used in RCTs to perform a
cost-utility analysis. As confirmed by the current study, most
general health utility instruments are not appropriate to
measure changes after cochlear implantation (Zeitler et al.,
2008; Kuthubutheen et al., 2015; Ramakers et al., 2016).
For example, the EQ-5D and VAS health instruments do
not incorporate a hearing element, and are therefore not
sensitive to detect change in QoL as a result of cochlear
implantation (Kraaijenga et al., 2017). Moreover, ceiling
effects of EQ-5D and TTO were observed, making it even
more challenging to detect improvement. Thus, for RCTs
on cost-utility analysis, the use of a QoL instrument with a
hearing element in cochlear implant studies, for example the
HUI3, seems appropriate (Eapen et al., 2009; Kraaijenga et al.,
2017). As illustrated in Figure 3, HUI3 scores improved after
UCI and simBiCI when compared to the situation before
implantation. This finding corresponds to previously published
data (Kraaijenga et al., 2017). Nonetheless, to detect smaller
differences, such as the additional effect of a second CI in
the UCI/seqBiCI group or differences between simBiCI and
seqBiCI the HUI3 is not sensitive enough. Compared to QoL
questionnaires, QoH questionnaires detected the largest benefit
of cochlear implantation, corresponding with previous findings
(Summerfield et al., 2006; Olze et al., 2012).
The nature of the complications that occurred during our trial
were in line with a previous study, in which vertigo, tinnitus
TABLE 5 | Results from a logistic regression analysis with an autoregressive residual covariance matrix (generalized estimating equations type) for the presence of
tinnitus burden.
Parameter Mean Standard deviation Odds ratio Lower bound 95% CI Upper bound 95% CI P-value
Treatment −1.110 0.7918 0.330 0.070 1.556 0.161
Year 2 −0.278 0.5155 0.758 0.276 2.080 0.590
Year 3 −0.578 0.6006 0.561 0.173 1.822 0.336
Year 4 −0.869 0.6452 0.419 0.118 1.485 0.178
Seq × year 2 0.637 0.6122 1.891 0.569 6.277 0.298
Seq × year 3 −0.833 0.8966 0.435 0.075 2.520 0.353
Seq × year 4 0.610 0.7606 1.840 0.414 8.172 0.423
Tinnitus baseline 2.404 0.7202 11.068 2.698 45.401 0.001
Reference treatment group = simBiCI. Reference year = year 1. The final model contained the following variables: time + treatment + time × treatment + baseline tinnitus
burden presence. SimBiCI, simultaneous bilateral cochlear implantation; seq, unilateral cochlear implantation/sequential bilateral cochlear implantation group. Bold value
means statistical significance.
TABLE 6 | Complications that occurred in this randomized controlled trial during 4 years of follow-up.
Adverse events SimBiCI UCI/SeqBiCI Onset of complication
Vertigo/dizziness 1 0 1 year after simBiCI
Dysfunction of cochlear implant 1 0 4 years after simBiCI
Flap necrosis leading to skin defect 0 1 10 months after seqBiCI
Facial nerve paresis 0 1 10 days after seqBiCI
Acute otitis media 0 1 Two weeks after seqBiCI
Pain 1 1 2 years after simBiCI; 5 months after UCI
Wound infection 0 1 Within 1 month after seqBiCI
Perception of extra sounds 0 1 Within 1 month after seqBiCI
SimBiCI, simultaneous bilateral cochlear implantation; UCI/seqBiCI, unilateral cochlear implantation/sequential bilateral cochlear implantation.
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and device failure were among the most reported complications
after cochlear implantation (Farinetti et al., 2014). Due to the
low sample size, the complication rate could not accurately be
compared with literature.
Strengths and Limitations
The major strength of the current study is the study design.
Since allocation bias is excluded, an RCT provides a high level
of evidence (level I). Data were prospectively gathered at the
same time points for all participants to ensure consistency in
reported outcomes. Furthermore, the study design enabled us
to examine multiple outcomes: BiCI versus UCI (and bimodal),
simBiCI versus seqBiCI and UCI versus seqBiCI. Another
strength is the longitudinal method for data analyses (GEE)
since it generates more power to detect differences. These
strengths add scientific value to knowledge based on previously
published studies.
A possible limitation of this study is the relatively small
sample size that made it difficult to detect differences in
secondary outcomes. The sample size calculation was based on
a power analysis aiming at the primary outcome measure. It
was performed under the assumption that the increase in power
due to repeated measurements would be sufficient for a time
by intervention group interaction in the analysis, effectively
describing and testing the intervention effect over time. We
decided to calculate the sample size in this manner, since
a sample size calculation for repeated measurement requires
both accurate means (and standard deviations) of the outcome
for each time point as well as the correlation (or covariance)
between the measurements at different time points. An accurate
estimate for especially the correlations was not available at
the moment of conception of the trial in 2008. Longitudinal
analyses however, have more power compared to cross-sectional
analyses because of the repeated observations at the individual
level. This approach may have compensated for the lack of
power. Three participants were lost to follow-up. This could
have led to a bias in treatment effect. However, the sample
size calculation incorporated loss to follow-up up to five
participants per group. Moreover, sensitivity analyses showed
comparable results to the original analyses regarding effect
sizes. The localization abilities were scored as percent correct
in three different loudspeaker configurations. In retrospect,
presenting these results as a mean error in degrees azimuth
would be more valuable than a percent correct score. However,
our set-up did not allow us to extract mean error data. HAs
were not fitted before every test session. In addition, the
noise reduction method may have differed per participant. The
rehabilitation was done according to the standards of each
CI center. Since we used a block randomization per center,
possible differences between centers could not have affected the
outcome difference between groups. Another possible limitation
is the use of logistic regression instead of linear regression
for the tinnitus outcomes. Continuous data provide more
information than dichotomous data. We only used the presence
of tinnitus and not the THI and TQ scores. Since participants
not suffering from tinnitus did not complete the questionnaires,
the THI and TQ scores of these patients were lacking. Linear
regression analysis with all these missing data would result in
biased results.
CONCLUSION
In this RCT, we evaluated the behavioral and self-reported
outcomes after simBiCI compared with UCI/seqBiCI in adult
patients with severe-to-profound SNHL with marginal benefit
of HAs (aided CVC phoneme score of ≤50%) longitudinally.
In the first 2 years of this study, patients after UCI performed
significantly worse than patients after simBiCI, on various spatial
hearing and localization outcomes. They showed significant
improvement after seqBiCI 2 years later and reached the same
amount of benefit as the simBiCI group after 4 years of follow-
up. Although the interval between sequential implantation
was only 2 years, our results show a significant benefit of
bilateral implantation both after simultaneous and sequential
implantation over UCI with or without a contralateral HA.
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